Gezien het succes van de CAR-T Celtherapie voor Multiple Myeloma (ziekte van Kahler) hebben Johnson & Johnson en Legend Biotech beslist om bijkomende investeringen te doen om zo de capaciteit verder uit te breiden.
Gezien het succes van de CAR-T Celtherapie voor Multiple Myeloma (ziekte van Kahler) hebben Johnson & Johnson en Legend Biotech beslist om bijkomende investeringen te doen om zo de capaciteit verder uit te breiden.
| Cookie | Duur | Beschrijving |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |